Spikevax (previously COVID-19 Vaccine Moderna)

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2

Available from:

Moderna Biotech Spain, S.L.

ATC code:

J07BN01

INN (International Name):

COVID-19 mRNA vaccine, elasomeran, elasomeran / imelasomeran, elasomeran / davesomeran, andusomeran

Therapeutic group:

cjepiva

Therapeutic area:

COVID-19 virus infection

Therapeutic indications:

Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. Spikevax bivalent Original/Omicron BA. 1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against COVID-19. Spikevax bivalent Original/Omicron BA. 4-5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.  Spikevax XBB. 5 is indicated for active immunisation to prevent COVID 19 caused by SARS-CoV-2 in individuals 6 months of age and older. The use of this vaccine should be in accordance with official recommendations.

Product summary:

Revision: 41

Authorization status:

odobren

Authorization date:

2021-01-06

Patient Information leaflet

                                155
B. UPUTA O LIJEKU
156
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
SPIKEVAX 0,2 MG/ML DISPERZIJA ZA INJEKCIJU
SPIKEVAX 0,1 MG/ML DISPERZIJA ZA INJEKCIJU
SPIKEVAX 50 MIKROGRAMA DISPERZIJA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
CJEPIVO PROTIV COVID-19 (MRNA)
elasomeran
Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Prijavom svih sumnji na nuspojavu i Vi možete pomoći.
Za postupak prijavljivanja
nuspojava, pogledajte dio 4.
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO ŠTO PRIMITE OVO CJEPIVO
JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili
medicinskoj sestri.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika, ljekarnika ili medicinsku
sestru. To uključuje i svaku moguću nuspojavu koja nije navedena u
ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Spikevax i za što se koristi
2.
Što morate znati prije nego što primite Spikevax
3.
Kako se daje Spikevax
4.
Moguće nuspojave
5.
Kako čuvati Spikevax
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE SPIKEVAX I ZA ŠTO SE KORISTI
Spikevax je cjepivo koje se koristi za sprječavanje bolesti COVID-19
uzrokovane virusom
SARS-CoV-2. Daje se odraslima i djeci u dobi od 6 mjeseci i starijima.
Djelatna tvar u cjepivu
Spikevax je mRNA koja kodira protein šiljka virusa SARS-CoV-2. mRNA
se nalazi u nanočesticama
lipida SM-102.
Budući da Spikevax ne sadrži virus, ne može Vas zaraziti s
COVID-19.
KAKO DJELUJE CJEPIVO
Spikevax potiče prirodnu obranu tijela (imunosni sustav). Cjepivo
djeluje tako što potiče tijelo na
stvaranje zaštite (protutijela) protiv virusa koji uzrokuje COVID-19.
Spikevax koristi tvar pod
nazivom glasnička ribonukleinska kiselina (mRNA) za prenošenje uputa
koje stanice u tijelu mogu
koristiti za proizvodnju proteina šiljka koji se također nalazi na
virusu. Stanice tada proizvode
protutijela protiv proteina šiljka za 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Od zdravstvenih radnika se traži da prijave svaku sumnju
na nuspojavu za ovaj lijek. Za
postupak prijavljivanja nuspojava vidjeti dio 4.8.
1.
NAZIV LIJEKA
Spikevax 0,2 mg/ml disperzija za injekciju
Spikevax 0,1 mg/ml disperzija za injekciju
Spikevax 50 mikrograma disperzija za injekciju u napunjenoj štrcaljki
cjepivo protiv COVID-19 (mRNA)
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
TABLICA
1. KVALITATIVNI I KVANTITATIVNI SASTAV PREMA JAČINI I VRSTI SPREMNIKA
JAČINA
SPREMNIK
DOZA (DOZE)
SASTAV PO DOZI
SPIKEVAX
0,2
MG/ML
DISPERZIJA ZA
INJEKCIJU
Višedozna
bočica (crvena
_flip-off_
kapica)
Najviše 10 doza od
0,5 ml
Jedna doza (0,5 ml) sadrži
100 mikrograma elasomerana,
mRNA cjepiva protiv bolesti
COVID-19 (modificiranih
nukleozida) (u nanočesticama
lipida).
Najviše 20 doza od
0,25 ml
Jedna doza (0,25 ml) sadrži
50 mikrograma elasomerana, mRNA
cjepiva protiv bolesti COVID-19
(modificiranih nukleozida) (u
nanočesticama lipida).
SPIKEVAX
0,1
MG/ML
DISPERZIJA ZA
INJEKCIJU
Višedozna
bočica (plava
_flip-off_
kapica)
5 doza od 0,5 ml
Jedna doza (0,5 ml) sadrži
50 mikrograma elasomerana, mRNA
cjepiva protiv bolesti COVID-19
(modificiranih nukleozida) (u
nanočesticama lipida).
Najviše 10 doza od
0,25 ml
Jedna doza (0,25 ml) sadrži
25 mikrograma elasomerana, mRNA
cjepiva protiv bolesti COVID-19
(modificiranih nukleozida) (u
nanočesticama lipida).
SPIKEVAX
50
MIKROGRAMA
DISPERZIJA ZA
INJEKCIJU U
NAPUNJENOJ
ŠTRCALJKI
Napunjena
štrcaljka
1 doza od 0,5 ml
Samo za jednokratnu
primjenu.
Nemojte koristiti
napunjenu štrcaljku
za davanje
djelomičnog
volumena od 0,25 ml.
Jedna doza (0,5 ml) sadrži
50 mikrograma elasomerana, mRNA
cjepiva protiv bolesti COVID-19
(modificiranih nukleozida) (u
nanočesticama lipida).
3
Elasomeran je jednolančana glasnička RNA (mRNA) s kapom na 5' kraju,
koja kodira protein šiljka
(engl.
_spike_
, S) virusa SARS-CoV-2 (izvorni), dobivena
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 01-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 01-02-2024
Public Assessment Report Public Assessment Report Bulgarian 28-09-2023
Patient Information leaflet Patient Information leaflet Spanish 01-02-2024
Public Assessment Report Public Assessment Report Spanish 28-09-2023
Patient Information leaflet Patient Information leaflet Czech 01-02-2024
Public Assessment Report Public Assessment Report Czech 28-09-2023
Patient Information leaflet Patient Information leaflet Danish 01-02-2024
Public Assessment Report Public Assessment Report Danish 28-09-2023
Patient Information leaflet Patient Information leaflet German 01-02-2024
Public Assessment Report Public Assessment Report German 28-09-2023
Patient Information leaflet Patient Information leaflet Estonian 01-02-2024
Public Assessment Report Public Assessment Report Estonian 28-09-2023
Patient Information leaflet Patient Information leaflet Greek 01-02-2024
Public Assessment Report Public Assessment Report Greek 28-09-2023
Patient Information leaflet Patient Information leaflet English 01-02-2024
Public Assessment Report Public Assessment Report English 28-09-2023
Patient Information leaflet Patient Information leaflet French 01-02-2024
Public Assessment Report Public Assessment Report French 28-09-2023
Patient Information leaflet Patient Information leaflet Italian 01-02-2024
Public Assessment Report Public Assessment Report Italian 28-09-2023
Patient Information leaflet Patient Information leaflet Latvian 01-02-2024
Public Assessment Report Public Assessment Report Latvian 28-09-2023
Patient Information leaflet Patient Information leaflet Lithuanian 01-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 01-02-2024
Public Assessment Report Public Assessment Report Lithuanian 28-09-2023
Patient Information leaflet Patient Information leaflet Hungarian 01-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 01-02-2024
Public Assessment Report Public Assessment Report Hungarian 28-09-2023
Patient Information leaflet Patient Information leaflet Maltese 01-02-2024
Public Assessment Report Public Assessment Report Maltese 28-09-2023
Patient Information leaflet Patient Information leaflet Dutch 01-02-2024
Public Assessment Report Public Assessment Report Dutch 28-09-2023
Patient Information leaflet Patient Information leaflet Polish 01-02-2024
Public Assessment Report Public Assessment Report Polish 28-09-2023
Patient Information leaflet Patient Information leaflet Portuguese 01-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 01-02-2024
Public Assessment Report Public Assessment Report Portuguese 28-09-2023
Patient Information leaflet Patient Information leaflet Romanian 01-02-2024
Public Assessment Report Public Assessment Report Romanian 28-09-2023
Patient Information leaflet Patient Information leaflet Slovak 01-02-2024
Public Assessment Report Public Assessment Report Slovak 28-09-2023
Patient Information leaflet Patient Information leaflet Slovenian 01-02-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 01-02-2024
Public Assessment Report Public Assessment Report Slovenian 28-09-2023
Patient Information leaflet Patient Information leaflet Finnish 01-02-2024
Public Assessment Report Public Assessment Report Finnish 28-09-2023
Patient Information leaflet Patient Information leaflet Swedish 01-02-2024
Public Assessment Report Public Assessment Report Swedish 28-09-2023
Patient Information leaflet Patient Information leaflet Norwegian 01-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 01-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 01-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 01-02-2024